Literature DB >> 22083265

Cause-specific mortality following radical prostatectomy.

S Shikanov1, M Kocherginsky, A L Shalhav, S E Eggener.   

Abstract

BACKGROUND: To evaluate cause-specific mortality following radical prostatectomy (RP) in a population cohort of US men adjusting for competing risks.
METHODS: The Surveillance, Epidemiology and End Results (SEER) database was used to identify 120,392 men undergoing RP for clinically localized prostate cancer between 1988 and 2003. Cause-specific mortality data were extracted through 2006 and cumulative incidence was estimated using a competing risks approach.
RESULTS: The stage distribution of the cancers was 32% local, 28% regional, 40% unknown, and 80% of tumors Gleason ≤ 7. Median follow-up was 7 years. The 15-year prostate cancer-specific mortality was 5.3% and the non-prostate cancer mortality was 30.6%. Stage, grade and race had minimal impact on non-prostate cancer mortality. At 15 years following surgery, mortality due to cardiovascular diseases was 11%, other cancers 9.1%, and other causes 10.5%. Among men ≥ 65 years, 15-year cancer-specific mortality was 6% and non-prostate cancer mortality was 40.8%.
CONCLUSIONS: Following RP, death from cardiovascular diseases, other cancers, and other causes is far more common than death from prostate cancer. In men diagnosed with prostate cancer, significant efforts should be made to prevent, diagnose, and treat these diseases.

Entities:  

Mesh:

Year:  2011        PMID: 22083265     DOI: 10.1038/pcan.2011.55

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  20 in total

1.  Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients.

Authors:  Pierpaolo Alongi; Alessandro Stefano; Albert Comelli; Riccardo Laudicella; Salvatore Scalisi; Giuseppe Arnone; Stefano Barone; Massimiliano Spada; Pierpaolo Purpura; Tommaso Vincenzo Bartolotta; Massimo Midiri; Roberto Lagalla; Giorgio Russo
Journal:  Eur Radiol       Date:  2021-01-14       Impact factor: 5.315

2.  Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care?

Authors:  Kathryn E Weaver; Randi E Foraker; Catherine M Alfano; Julia H Rowland; Neeraj K Arora; Keith M Bellizzi; Ann S Hamilton; Ingrid Oakley-Girvan; Gretchen Keel; Noreen M Aziz
Journal:  J Cancer Surviv       Date:  2013-02-16       Impact factor: 4.442

Review 3.  PET imaging of recurrent and metastatic prostate cancer with novel tracers.

Authors:  Francesca V Mertan; Liza Lindenberg; Peter L Choyke; Baris Turkbey
Journal:  Future Oncol       Date:  2016-08-16       Impact factor: 3.404

4.  Nearly All Cancer Survivors Return to Primary Care.

Authors:  Laura C Pinheiro; Mangala Rajan; Monika M Safford; David M Nanus; Lisa M Kern
Journal:  J Am Board Fam Med       Date:  2022 Jul-Aug       Impact factor: 2.395

5.  Cardiovascular disease prevention and management of pre-existent cardiovascular disease in a cohort of prostate cancer survivors.

Authors:  Aaron J Katz; Ronald C Chen; Deborah S Usinger; Susanne M Danus; Leah L Zullig
Journal:  J Cancer Surviv       Date:  2022-07-05       Impact factor: 4.062

6.  Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy.

Authors:  Berrend G Muller; Aradhana Kaushal; Sandeep Sankineni; Elena Lita; Anthony N Hoang; Arvin K George; Soroush Rais-Bahrami; Jochen Kruecker; Pingkun Yan; Sheng Xu; Jean J de la Rosette; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Urol Oncol       Date:  2015-08-08       Impact factor: 3.498

Review 7.  Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.

Authors:  Francesca V Mertan; Matthew D Greer; Sam Borofsky; Ismail M Kabakus; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Top Magn Reson Imaging       Date:  2016-06

Review 8.  [The role of PSMA PET-CT in patients with metastatic prostate cancer].

Authors:  J von Hardenberg; K-A Büsing; P Nuhn; M Ritter
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639

Review 9.  [The role of PSMA PET-CT in patients with metastatic prostate cancer].

Authors:  J von Hardenberg; K-A Büsing; P Nuhn; M Ritter
Journal:  Radiologe       Date:  2018-03       Impact factor: 0.635

10.  Age-dependent increased odds of cardiovascular risk factors in cancer survivors: Canadian Longitudinal Study on Aging cohort.

Authors:  A A Kirkham; E Pituskin; S E Neil-Sztramko
Journal:  Curr Oncol       Date:  2020-08-01       Impact factor: 3.109

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.